ACBMOTCServices-Amusement & Recreation ServicesFiscal year ends December 31
ACRO BIOMEDICAL CO., LTD.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.03+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.56M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.0253 (+3,614%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
ACRO BIOMEDICAL CO., LTD. reported revenue of $0 for the twelve months to Jun 30, 2026.
Revenue
$0
TTM Q2 2026
Operating income
-$209.30K
TTM Q2 2026
EPS, diluted
$0.00
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.56M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$140.41K
- EPS, diluted
- $0.00
- Book value per share
- -$0.01
- Diluted shares
- 60M
Eleven years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
$0
Gross profit
–
Operating income
-$209.30K
Net income
-$140.41K
EPS, diluted
$0.00
Reported periodTrailing twelve months